Early detection and treatment of schizophrenia: how early?

Objective:  Whereas early detection and therapy of schizophrenic psychoses until some time ago concentrated on frank schizophrenia, during the last years some centres have also started to treat patients even before a clear diagnosis could be established. This paper attempts to discuss if and when th...

Full description

Saved in:
Bibliographic Details
Published inActa psychiatrica Scandinavica Vol. 113; no. s429; pp. 73 - 80
Main Authors Riecher-Rössler, A., Gschwandtner, U., Borgwardt, S., Aston, J., Pflüger, M., Rössler, W.
Format Journal Article Conference Proceeding
LanguageEnglish
Published Oxford, UK Munksgaard International Publishers 01.02.2006
Blackwell
Blackwell Publishing Ltd
Subjects
Online AccessGet full text
ISSN0001-690X
0065-1591
1600-0447
DOI10.1111/j.1600-0447.2005.00722.x

Cover

More Information
Summary:Objective:  Whereas early detection and therapy of schizophrenic psychoses until some time ago concentrated on frank schizophrenia, during the last years some centres have also started to treat patients even before a clear diagnosis could be established. This paper attempts to discuss if and when this is justified in the light of recent research. Method:  Mini review of literature. Results:  The rationale for early detection and treatment of schizophrenia is based on several observations: diagnosis and treatment of schizophrenia are often seriously delayed. Consequences of the disease are severe already in the early undiagnosed phase of the disorder and early treatment seems to improve the course of the disease. It can therefore be stated quite safely that patients should be treated as early as possible. However, the question of how early has not been sufficiently answered up to now. Conclusion:  We are at the moment in an ethical dilemma between either diagnosing and treating this disorder too late or too early. The only way and prerequisite for solving this dilemma is a more reliable identification of individuals at risk and the beginning disease process.
Bibliography:ArticleID:ACPS722
istex:F3CDE5DA9A16376C1F8840A5DD0B3BE54936BAC8
ark:/67375/WNG-BBT2KHMX-M
Parts of this paper were in a preliminary version read at the 3rd International Zurich Conference on Clinical and Social Psychiatry, Zurich, September 25–27, 2003. The symposium as well as publication of this supplement were sponsored by Eli Lilly, Suisse.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0001-690X
0065-1591
1600-0447
DOI:10.1111/j.1600-0447.2005.00722.x